{"name":"Jacqueline Garcia, MD","slug":"jacqueline-garcia-md","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxQVzgwR1dXdGJHRG5zeW5xSVotUXpjZWtmTFpmMDg2Uk9UUjVMMG4yY1JXdlgwMDVoRXlnRThmMkgtTzZwNUk3YWFwbjg5cGNDODFfV19ON2pkZjFremU0YXU4bUtjWDBBSC1YWmNlaEZaQ3UwRkdDcVFPTFpLekU2RGtQZm1TTlJaY3BJYzNoempDZ0h6aExwTHp0R0NpS3BVbHB3?oc=5","date":"2026-01-20","type":"pipeline","source":"Dana-Farber Cancer Institute","summary":"Ten Cancer-Related Breakthroughs Giving Us Hope in 2026 - Dana-Farber Cancer Institute","headline":"Ten Cancer-Related Breakthroughs Giving Us Hope in 2026 - Dana","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTE1qWURpRktmX0JoZzNrcEQ3RDlOakJRcHNtSTVmdHpMQWZ6Q296eWJWOTlpMnI2X3ZDQ2JaT2c3WnZ2UWtobU1UQ3k5Z3o2bW51Uko2R3E5eVBMN1dhZDVLZ0dWakdfM2I4QUpVUzRwY3VDVzJkcmVraEFjRQ?oc=5","date":"2022-05-02","type":"pipeline","source":"Wiley","summary":"Defining disease modification in myelofibrosis in the era of targeted therapy - Wiley","headline":"Defining disease modification in myelofibrosis in the era of targeted therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTFBzVEoxX1BuYURYWEN5TkdoVGJ2bHNPOGVHb2pEYTZSY0tmY3hlSlp6ak5RaWFTeWVoNkZOWlp1SVJIWmpzU2RYYnRHdDBleS05QmhBcTg0LXVRdE0wZ01PMg?oc=5","date":"2020-08-12","type":"pipeline","source":"NEJM","summary":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia - NEJM","headline":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE9QeEN6Sk1UajEyNlZBYUxDMERtODBSOG0wdTJsTHZyTThyS1JObG5PS0d5c1Npalh0RkFRTWpoQVB5dDBsV0szS2xfZVVBVGRpVDE2RENuR2ZsTlpoN3hR?oc=5","date":"2020-08-12","type":"pipeline","source":"NEJM","summary":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia - NEJM","headline":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}